Low-Dose Naltrexone Side Effects: Withdrawal and Discontinuation Syndrome Explained

Does low-dose naltrexone cause withdrawal?

LDN has no FDA-approved label of its own [2][5]. The closest regulatory statement is in the 50 mg tablet label: naltrexone is a pure opioid antagonist that does not lead to physical or psychological dependence, and tolerance to its opioid-blocking effect is not known to occur [1]. That statement describes the approved 50 mg tablets at approved doses, not a compounded 0.5 to 6 mg LDN product [1][2].

What the labels say about stopping approved naltrexone

The warnings on the oral and injectable labels about stopping concern lower opioid tolerance after treatment ends, not a withdrawal syndrome [1][3]. A dose of opioid that was previously tolerated can then cause life-threatening intoxication, and fatal overdoses have been reported in people who used opioids after discontinuing naltrexone [1]. The injectable label adds the end of a monthly dosing interval and a missed dose as times of increased vulnerability [3].

The withdrawal risk that is documented: starting naltrexone

Naltrexone precipitates withdrawal in someone who is physically dependent on opioids. The oral label says symptoms usually appeared within 5 minutes of ingestion and lasted up to 48 hours; confusion, sleepiness, visual hallucinations, and fluid losses requiring intravenous fluids occurred, and postmarketing cases needed hospital admission and sometimes intensive care [1]. The tablet label recommends an opioid-free interval of at least 7 to 10 days for short-acting opioids and says people switching from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [1]. The injection label also recommends at least 7 to 10 opioid-free days [3]. The tablet label's contraindication for people receiving opioid analgesics is written without a dose exception [1].

Side effects during LDN use, not after stopping

In a meta-analysis of four randomized fibromyalgia trials with 222 patients, vivid dreams and nausea were more common with LDN than placebo, and serious adverse events did not differ significantly [4]. In a 12-month trial of 98 women with fibromyalgia, adverse events were reported by 33 of 48 on LDN 4.5 mg (68.8%) and 36 of 50 on placebo (72%); most were mild and transient, and there were no treatment-related serious events [6]. These are on-treatment reports, not reports after the last dose.

What the evidence does not settle

A 2026 narrative review of 105 studies, including 15 randomized trials, concluded that current evidence does not support routine clinical use of LDN [2]. The same review describes the proposed low-dose mechanisms, including Toll-like receptor 4 effects and transient opioid blockade, as largely theoretical and speculative [2].